Prostate cancer susceptibility loci identified on chromosome 12 in african americans

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Bonilla, Carolina ^a   Hooker, Stanley ^b   Mason, Tshela ^c   Bock, Cathryn H ^d   Kittles, Rick A ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF CHICAGO   (United States)

^c HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; APOPTOSIS REGULATORY PROTEIN; PROSTATE APOPTOSIS RESPONSE 4 PROTEIN; PROSTATE APOPTOSIS RESPONSE-4 PROTEIN;

ADULT; AFRICAN AMERICAN; ARTICLE; CANCER SUSCEPTIBILITY; CHROMOSOME 12; CONTROLLED STUDY; GENE LOCUS; GENETIC IDENTIFICATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; PROSTATE CANCER; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; AFRICA; AGED; CARCINOMA; CASE CONTROL STUDY; CAUCASIAN; ETHNOLOGY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PROSTATE TUMOR;

AFRICA, WESTERN; AFRICAN AMERICANS; AGED; APOPTOSIS REGULATORY PROTEINS; CARCINOMA; CASE-CONTROL STUDIES; CHROMOSOMES, HUMAN, PAIR 12; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS;

EID: 79951886089     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016044     Document Type: Article

References (27)

1. Reddy S, Shapiro M, Morton R, Brawley OW, (2003) Prostate cancer in black and white Americans. Cancer Metastasis Reviews 22: 83-6.
2. Whitman EJ, Pomerantz M, Chen Y, Chamberlin MM, Furusato B, et al. (2010) Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomy. Cancer Epidemiology, Biomarkers & Prevention 19: 1-8 doi:10.1158/1055-9965.EPI-08-1111.
3. Schaid DJ, Stanford JL, McDonnell SK, Suuriniemi M, McIntosh L, et al. (2007) Genome-wide linkage scan of prostate cancer Gleason score and confirmation of chromosome 19q. Human Genetics 121: 729-35 doi:10.1007/s00439-007-0368-5.
4. Yin M, Wei S, Wei Q, (2009) Vitamin D Receptor Genetic Polymorphisms and Prostate Cancer Risk: A Meta-analysis of 36 Published Studies. International Journal of Clinical and Experimental Medicine 2: 159-175.
5. Smith MW, Patterson N, Lautenberger JA, Truelove AL, McDonald GJ, et al. (2004) A high-density admixture map for disease gene discovery in African Americans. American Journal of Human Genetics 74: 1001-13 doi:10.1086/420856.
6. Fan J, Gunderson K, Bibikova M, Yeakley J, Chen J, et al. (2006) Illumina Universal Bead Arrays. Methods in Enzymology 410: 57-73 doi:10.1016/S0076-6879(06)10003-8.
7. Tang K, Fu DJ, Julien D, Braun A, Cantor CR, et al. (1999) Chip-based genotyping by mass spectrometry. Proceedings of the National Academy of Sciences of the United States of America 96: 10016-20.
8. Pritchard JK, Stephens M, Donnelly P, (2000) Inference of population structure using multilocus genotype data. Genetics 155: 945-59.
9. Barrett JC, Fry B, Maller J, Daly MJ, (2005) Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
10. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, et al. (2007) PLINK: A tool set for whole-genome association and population-based linkage analyses. American Journal of Human Genetics 81: 559-75 doi:10.1086/519795.
11. Purcell S, Cherny SS, Sham PC, (2003) Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19: 149-50.
12. Coassin S, Brandstätter A, Kronenberg F, (2010) Lost in the space of bioinformatic tools: a constantly updated survival guide for genetic epidemiology. The GenEpi Toolbox. Atherosclerosis 209: 321-35 doi:10.1016/j.atherosclerosis.2009.10.026.
13. Hernandez W, Grenade C, Santos ER, Bonilla C, Ahaghotu C, et al. (2007) IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans. Carcinogenesis 28: 2154-2159 doi:10.1093/carcin/bgm190.
14. Roff A, Wilson R, (2008) A novel SNP in a vitamin D response element of the CYP24A1 promoter reduces protein binding, transactivation, and gene expression. The Journal of Steroid Biochemistry and Molecular Biology 112: 47-54 doi:10.1016/j.jsbmb.2008.08.009.
15. Alagarasu K, Selvaraj P, Swaminathan S, Narendran G, Narayanan PR, (2009) 5′ regulatory and 3′ untranslated region polymorphisms of vitamin D receptor gene in south Indian HIV and HIV-TB patients. Journal of Clinical Immunology 29: 196-204 doi:10.1007/s10875-008-9234-z.
16. Taylor JA, Hirvonen A, Watson M, Pittman G, Mohier JL, et al. (1996) Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Research 56: 4108-4110.
17. Ingles SA, Coetzee GA, Ross RK, Henderson BE, Kolonel LN, et al. (1998) Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Research 58: 1620-3.
18. Holick CN, Stanford JL, Kwon EM, Ostrander EA, Nejentsev S, et al. (2007) Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiology, Biomarkers & Prevention 16: 1990-9 doi:10.1158/1055-9965.EPI-07-0487.
19. Gsur A, Madersbacher S, Haidinger G, Schatzl G, Marberger M, et al. (2002) Vitamin D receptor gene polymorphism and prostate cancer risk. The Prostate 51: 30-34 doi:10.1002/pros.10064.
20. Chen L, Davey Smith G, Evans DM, Cox A, Lawlor DA, et al. (2009) Genetic variants in the vitamin D receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review. Cancer Epidemiology, Biomarkers & Prevention 18: 2874-81 doi:10.1158/1055-9965.EPI-09-0544.
21. Hawkins GA, Cramer SD, Zheng SL, Isaacs SD, Wiley KE, et al. (2002) Sequence variants in the human 25-hydroxyvitamin D3 1-alpha-hydroxylase (CYP27B1) gene are not associated with prostate cancer risk. The Prostate 53: 175-8 doi:10.1002/pros.10144.
22. Zapata-Benavides P, Méndez-Vázquez JL, González-Rocha TR, Zamora-Avila DE, Franco-Molina MA, et al. (2009) Expression of prostate apoptosis response (Par-4) is associated with progesterone receptor in breast cancer. Archives of Medical Research 40: 595-9 doi:10.1016/j.arcmed.2009.08.007.
23. Fernandez-Marcos PJ, Abu-Baker S, Joshi J, Galvez A, Castilla EA, et al. (2009) Simultaneous inactivation of Par-4 and PTEN in vivo leads to synergistic NF-kappaB activation and invasive prostate carcinoma. Proceedings of the National Academy of Sciences of the United States of America 106: 12962-7 doi:10.1073/pnas.0813055106.
24. Ioannidis JPA, (2005) Why most published research findings are false. PLoS Medicine 2: e124 doi:10.1371/journal.pmed.0020124.
25. Patterson N, Hattangadi N, Lane B, Lohmueller KE, Hafler DA, et al. (2004) Methods for high-density admixture mapping of disease genes. The American Journal of Human Genetics 74: 979-1000.
26. Berndt S, Dodson J, Huang W, Nicodemus K, (2006) A systematic review of Vitamin D Receptor gene polymorphisms and prostate cancer risk. The Journal of Urology 175: 1613-1623 doi:10.1016/S0022-5347(05)00958-4.
27. Andersson P, Varenhorst E, Söderkvist P, (2006) Androgen receptor and vitamin D receptor gene polymorphisms and prostate cancer risk. European Journal of Cancer 42: 2833-7 doi:10.1016/j.ejca.2006.06.030.